Lecanemab induces phenotypic change in glial and microglial cells in Alzheimer’s disease models: vitro and vivo evidences
Noelle Callizot, Alexandre Henriques, Steidl Esther, Laura Rouviere, Bilal El Waly, Alexandre Wojcinski, Philippe Poindron · 2025
Read Lecanemab induces phenotypic change in glial and microglial cells in Alzheimer’s disease models: vitro and vivo evidences by Noelle Callizot, Alexandre Henriques, Steidl Esther, Laura Rouviere, Bilal El Waly, Alexandre Wojcinski, Philippe Poindron (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712628.txt.
Description
Noelle Callizot and co-authors published a research paper in 2025 on how lecanemab, an approved drug for Alzheimer's disease, changes the brain's immune and support cells. The drug binds early clumps of amyloid, a protein that builds up in the illness. What it does to the cells that react to those clumps was still vague.
The team grew rat brain cells in dishes, harmed them with amyloid, and added the drug an hour before. They also gave the drug to aged mice with amyloid placed in the brain. Amyloid alone raised the share of attack-ready immune cells. The paper tracks how the drug shifts those cell states in both setups, which may help explain how it works.
Catalog record
| CREATOR | Noelle Callizot, Alexandre Henriques, Steidl Esther, Laura Rouviere, Bilal El Waly, Alexandre Wojcinski, Philippe Poindron |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |